updates in hepatocellular carcinoma - michigan cancer · 2019. 11. 5. · updates in hepatocellular...
TRANSCRIPT
![Page 1: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/1.jpg)
Updates in Hepatocellular Carcinoma
These slides are the property of the presenter. Do not duplicate without permission.
![Page 2: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/2.jpg)
The Global Impact of Liver Cancer
Akinyemiju T, et al. JAMA Oncol 2017.EASL CPG; J Hepatol 2018.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 3: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/3.jpg)
Incidence in the U.S.
White DL, et al. Gastro 2017.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 4: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/4.jpg)
Malignant Transformation
Normal liver
Liver cirrhosis
Hepatitis CHepatitis B
EthanolNASH
Epigenetic alterationsGenetic alterations
HCC[2]
Dysplastic nodules[1]
1. Tornillo L, et al. Lab Invest. 2002;82:547-553. 2. Verslype C, et al. AASLD 2007.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 5: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/5.jpg)
Incidence of HCC is rising
www.seer.cancer.gov
These slides are the property of the presenter. Do not duplicate without permission.
![Page 6: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/6.jpg)
HCC Mortality from 1990-2015…
Fitzmaurice, et al. JAMA Oncol 2017.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 7: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/7.jpg)
High Mortality Rates in HCC
Khalaf N, et al. CGH 2016.
518 untreated patients: survival stratified by stage
These slides are the property of the presenter. Do not duplicate without permission.
![Page 8: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/8.jpg)
HCC Risk Factors
El Serag HB. Gastro 2007, Bruix J. Hepatology 2010. Collier J. Hepatology 1998. Marrero JA. J Hepatol 2005.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 9: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/9.jpg)
Alcohol and HCC risk
Donato F, et al. Am J Epid 2002.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 10: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/10.jpg)
NAFLD and HCC risk
Kanwal F, et al. Gastro 2018.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 11: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/11.jpg)
HCC preventive interventions
These slides are the property of the presenter. Do not duplicate without permission.
![Page 12: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/12.jpg)
Modifying HCC risk
Singal AG. Clin Gastro Hep 2010. Nishiguchi S. Lancet 1995. Valla DC. Hepatology 1999. Lok AS. Gastro 2011.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 13: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/13.jpg)
Impact of Universal Vaccination in Taiwan
Chang MH. NEJM 1997
These slides are the property of the presenter. Do not duplicate without permission.
![Page 14: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/14.jpg)
Hep B viral load and HCC incidence
Chen CJ. JAMA 2006.
REVEAL Study (n=3,653)
10
6
4
2
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13
Cu
mu
lati
ve
inci
den
ce o
f H
CC
(% s
ub
ject
s)
12
8
Baseline HBV DNA level, copies/mL
≥106 (n=627)
105–<106 (n=349)
104–<105 (n=643)
300–<104 (n=1,161)
<300 (n=873)
Log rank test of trend
p<0.001
14.9%
12.2%
3.6%
1.4%1.3%
Year of follow-up
These slides are the property of the presenter. Do not duplicate without permission.
![Page 15: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/15.jpg)
Antiviral Therapy in Hepatitis BP
ati
en
ts w
ith
dis
ease
pro
gre
ss
ion
(%
)
Time to disease progression (months)
“Proof of Principle”
LiawY-F et al. N Engl J Med. 2004;351:1521-1531.
Lamivudine (n=436)
Placebo (n=215)
P=0.001
21%
9%
25
20
15
10
5
0
30181260 36
n=198
n=173
n=417
n=385
n=43
n=122
24
These slides are the property of the presenter. Do not duplicate without permission.
![Page 16: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/16.jpg)
HCV treatment reduces HCC risk
Kanwal, et al. Gastro 2017.
• SVR vs no SVR (0.90 vs 3.45 HCC/100 person-years; HR 0.28)• Cirrhosis + SVR vs. no Cirrhosis + SVR (1.82 vs 0.34/100 person-years; HR 4.73)
These slides are the property of the presenter. Do not duplicate without permission.
![Page 17: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/17.jpg)
Surveillance for HCC
El-Serag HB. Gut 2011. Trevisani F. Am J Gastro 2002.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 18: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/18.jpg)
Surveillance improves early stage diagnosis
Singal, et al. PLoS Med 2014.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 19: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/19.jpg)
Surveillance for HCC Reduces MortalityA Randomized Controlled Trial
Zhang BH. J Cancer Res Clin Oncol 2004.
Time (Years)
Su
rviv
al P
rob
abili
ty (%
)
0 1 2 3 4 50
.8
.6
.2
.4
Screening
Control
HCC-related mortality reduced by 37%
These slides are the property of the presenter. Do not duplicate without permission.
![Page 20: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/20.jpg)
Surveillance improves survival in cirrhosis
Singal, et al. PLoS Med 2014.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 21: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/21.jpg)
Surveillance for HCC
• Ultrasound every 6 months
• AFP with US increases sensitivity to 63.4% (clinical practice)
Bruix J, Sherman M. Hepatology 2010.Singal AG. AP&T 2009. Singal AG. Canc Epid Bio Prev 2012. Marrero JA. Gastro 2009.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 22: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/22.jpg)
Surveillance for HCC
Hepatology, 68(2), 2018
These slides are the property of the presenter. Do not duplicate without permission.
![Page 23: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/23.jpg)
Surveillance rates for HCC
Singal AG. J Gen Int Med 2012.
Pooled meta-analysis: <20% surveillance rates for cirrhotic patients
These slides are the property of the presenter. Do not duplicate without permission.
![Page 24: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/24.jpg)
PCP reported barriers to surveillance
Provider-reported Barriers Percent
Lack of knowledge about guidelines 68.2%
Competing interests in clinic 51.6%
Lack of time in clinic 41.5%
Difficulty recognizing at-risk patients 35.4%
Ultrasound capacity 23.0%
Doubt patients will complete 9.3%
Dalton-Fitzgerald, et al. CGH 2015.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 25: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/25.jpg)
Diagnosing HCC
These slides are the property of the presenter. Do not duplicate without permission.
![Page 26: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/26.jpg)
• Vascular supply of HCC arises from the hepatic artery through neovascularization.
• Multi-phase imaging is key
• Radiological hallmark: arterial hypervascularity with washout in the venous/delayed phase
Yu JS. Am J Roentgenol 1999
These slides are the property of the presenter. Do not duplicate without permission.
![Page 27: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/27.jpg)
Pre-contrast Arterial Phase Portal Venous/ Delayed
HCC Diagnosis
These slides are the property of the presenter. Do not duplicate without permission.
![Page 28: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/28.jpg)
Arterial phase 2-min delayed
5-min delayedArterial phase
Washout in HCCWashout in HCC
These slides are the property of the presenter. Do not duplicate without permission.
![Page 29: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/29.jpg)
Marrero, et al. Hepatology 2018.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 30: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/30.jpg)
30
HCC StagingPatient
TumorLiver
ECOG
PS
Child-
PughTNM
BCLC
• Staging is used for prognosis and to guide treatment
• Factors affecting staging systems
– Tumor stage
– Liver function
– Functional status
• Links stage with treatment options and prognosis
1. Llovet JM. Gastroenterol. 2005;40:225-235; 2. Marrero JA, et al. Clin Liver Dis. 2006;10:339-351; 3. Bruix J, et al. J Hepatol. 2001;35:421-430;
4. Llovet JM, et al. Semin Liver Dis. 1999;19:329-338; 5. Chevret S, et al. J Hepatol. 1999;31:133-141; 6. Schafer DF, et al. Lancet. 1999;353:1253-1257;
7. Leung T, et al. Cancer. 2002;94:1760-1769; 8. CLIP. Hepatology. 1998;28:751-755; 9. Makuuchi M, et al. World J Gastroenterol. 2006;12:828-829.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 31: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/31.jpg)
BCLC Staging System
Marrero JA. Hepatology 2005
100
Su
rviv
al P
rob
abili
ty 80
60
40
20
0
0 10 20 30 40 50 60 70
Log Rank PA vs. B P < .0001B vs. C P = .04C vs. D P = .01
A
B
CD
Time (Months)
BCLC Staging System
HCC Staging
• BCLC was best predictor of survival
• Homogeneity in survival across each stage
• Validated BCLC compared to other staging systems
These slides are the property of the presenter. Do not duplicate without permission.
![Page 32: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/32.jpg)
Barcelona Staging
Marrero, et al. Hepatology 2018.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 33: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/33.jpg)
Bruix J, Sherman M. J Hepatol 2011.
HCC Staging & Prognosis
These slides are the property of the presenter. Do not duplicate without permission.
![Page 34: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/34.jpg)
Treatment of Early Stage HCC
EASL CPG. J Hep 2018.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 35: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/35.jpg)
Outcome of Surgical Resection for HCC in Cirrhosis
Llovet JM. Hepatology 1999.
Patients with a single tumor <= 5 cm and Child A cirrhosis
Months
00
Pro
bab
ility
(%)
12 24 36 48
20
100
40
60
80
Log Rank 0.00001
60 72 84 96
Nl portal pressure, Bili <1
Portal pressure, Bili <1
Portal pressure, Bili 1
*Other surrogates for portal htn =
HVPG ≥ 10mmHg ; plt <100
These slides are the property of the presenter. Do not duplicate without permission.
![Page 36: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/36.jpg)
Four -Year Survival
0
10
20
30
40
50
60
70
80
Unselected 1991 Milan Criteria Other Dx
40%
75% 76%
%
Surviving
Mazzafero V. NEJM 1996.
Liver Transplant for HCC
These slides are the property of the presenter. Do not duplicate without permission.
![Page 37: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/37.jpg)
Intermediate HCC (Stage B)
These slides are the property of the presenter. Do not duplicate without permission.
![Page 38: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/38.jpg)
Chemoembolization
Prolongs 2-yr survival: 63% vs. 27% for best supportive care (p<0.001)
Llovet JM. Lancet 2002.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 39: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/39.jpg)
Radioembolization with Yttrium (Y90) microspheres in HCC (TARE)
Kulik LM. Hepatology. 2008. Salem R. Gastro 2010. Hilgard P. Hepatology 2010. Sangro B. Dig Dis 2009.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 40: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/40.jpg)
TARE likely has a role for Intermediate Stage HCC
Salem et al. Gastro 2016.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 41: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/41.jpg)
Advanced HCC (Stage C)
These slides are the property of the presenter. Do not duplicate without permission.
![Page 42: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/42.jpg)
SHARP: Overall Survival Sorafenib
Sorafenib median:46.3 weeks (10.7 months)(95% CI, 40.9-57.9)
Placebo median: 34.4 weeks (7.9 months) (95% CI, 29.4-39.4)
Llovet JM et al. NEJM 2008.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 43: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/43.jpg)
SHARP results
Llovet JM et al. NEJM 2008.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 44: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/44.jpg)
Subsequent negative HCC trials…
These slides are the property of the presenter. Do not duplicate without permission.
![Page 45: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/45.jpg)
Lenvatinib is non-inferior to Sorafenib
Kudo et al. Lancet 2018.
These slides are the property of the presenter. Do not duplicate without permission.
![Page 46: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/46.jpg)
Current treatment landscape…
These slides are the property of the presenter. Do not duplicate without permission.
![Page 47: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/47.jpg)
Henry Ford HCC: Multidisciplinary Approach
Radiation
Oncology
Pathology
Oncology
Radiology
Hepatobiliary
Surgery
Hepatology
These slides are the property of the presenter. Do not duplicate without permission.
![Page 48: Updates in Hepatocellular Carcinoma - Michigan Cancer · 2019. 11. 5. · Updates in Hepatocellular Carcinoma These slides are the property of the presenter. Do not duplicate without](https://reader035.vdocument.in/reader035/viewer/2022063011/5fc75813c2a2c80ee8535981/html5/thumbnails/48.jpg)
Conclusion – Key Learnings
These slides are the property of the presenter. Do not duplicate without permission.